Alnylam Pharmaceuticals (NASDAQ:ALNY) reported Q4 2017 earnings this Afternoon, coming in at ($1.48) per share, missing Wall Street’s estimates of ($1.03) per Share. Revenue for the quarter came in at $37.90 million beating analyst estimates of $19.31 million Recent Insider Trading for Alnylam Pharmaceuticals (NASDAQ:ALNY)
- On 1/4/2018 Michael Mason, VP, sold 36,745 with an average share price of $131.59 per share and the total transaction amounting to $4,835,274.55.
- On 12/20/2017 Laurie Keating, SVP, sold 6,249 with an average share price of $121.20 per share and the total transaction amounting to $757,378.80.
- On 12/1/2017 Laurie Keating, SVP, sold 30,000 with an average share price of $135.89 per share and the total transaction amounting to $4,076,700.00.
- On 11/22/2017 John Maraganore, CEO, sold 73,415 with an average share price of $130.90 per share and the total transaction amounting to $9,610,023.50.
- On 11/15/2017 John Maraganore, CEO, sold 74,000 with an average share price of $126.86 per share and the total transaction amounting to $9,387,640.00.
- On 11/2/2017 Dennis A Ausiello, Director, sold 20,000 with an average share price of $130.00 per share and the total transaction amounting to $2,600,000.00.
Recent Trading for Alnylam Pharmaceuticals (NASDAQ:ALNY) Shares of Alnylam Pharmaceuticals closed the previous trading session at 117.37 down -4.72 3.87% with 123.58999633789062 shares trading hands.